US equities
|
MU
$985.17
▼-4.26%
NVDA
$225.79
▼-1.52%
SNDK
$1,475.10
▼-6.75%
META
$747.56
▲+4.02%
SPCX
$163.59
▲+0.62%
AMD
$587.52
▼-3.38%
INTC
$100.85
▼-3.68%
TSLA
$379.79
▼-0.76%
MU
$985.17
▼-4.26%
NVDA
$225.79
▼-1.52%
SNDK
$1,475.10
▼-6.75%
META
$747.56
▲+4.02%
SPCX
$163.59
▲+0.62%
AMD
$587.52
▼-3.38%
INTC
$100.85
▼-3.68%
TSLA
$379.79
▼-0.76%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
(NQ:
IRWD
)
3.780
-0.040 (-1.05%)
Delayed Quote
Updated: 11:12 AM EDT, Oct 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ironwood Pharmaceuticals, Inc. - Class A Common Stock
< Previous
1
2
3
4
Next >
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 03, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
August 06, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
July 30, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
July 14, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
May 28, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)
May 27, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance
May 07, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)
May 04, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call
April 30, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
April 23, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
March 04, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook
February 25, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call
February 18, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
January 02, 2026
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance
November 10, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
August 07, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports First Quarter 2025 Results
May 07, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
April 30, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
April 25, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
April 22, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide
April 14, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
March 27, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
February 27, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
February 20, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
January 29, 2025
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 13, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
November 07, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
October 28, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
October 24, 2024
From
Ironwood Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
